On May 28, 2021 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported its participation in the following upcoming virtual investor conferences (Press release, Moderna Therapeutics, MAY 28, 2021, View Source [SID1234583274]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:00 a.m. ET
Goldman Sachs 42nd Annual Healthcare Conference on Wednesday, June 9, 2021 at 8:00 a.m. ET
A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at View Source A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

On May 28, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported the publication of its Interim Report for the period January – March 2021 (Press release, Allarity Therapeutics, MAY 28, 2021, View Source [SID1234583273]). The report is available as an attached document and on the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve Carchedi, CEO of Allarity Therapeutics, stated, "2021 has already been a year full of significant events for Allarity. We have initiated our IXEMPRA Phase 2 trial in Europe, and we made progress on multiple fronts in our effort to achieve U.S. marketing approval for dovitinib together with its DRP companion diagnostic, and we remain committed to filing the New Drug Application (NDA) for dovitinib later this year with the U.S. FDA. Moreover, we expanded our preclinical testing of stenoparib’s antiviral properties to include both the British and South African variant of Coronavirus. On the financial side, we have ceased to rely on convertible notes as our main source of funding. Instead, we have announced two new financing events, one a rights issue and one a U.S. $20M investment, the largest in our Company’s history, which is conditional on our company transforming into a U.S. company and listing on the U.S. Nasdaq Stock Market. I look forward to our achievement of further strategic milestones during the remainder of this year."

Summary of the Interim Report

Consolidated group revenue amounted to 0 MDKK (0 MDKK).
Consolidated group loss before depreciation amounted to -15.8 MDKK (-17.3 MDKK).
Consolidated group loss before net financials amounted to -16.0 MDKK (-17.6 MDKK).
Consolidated net result amounted to -17.6 MDKK (-15.4 MDKK).
Consolidated earnings per share (EPS) amounted to -0.08 DKK (-0.12 DKK).

2020 numbers in brackets.

Highlights during Q1 2021

January

On January 26, Allarity Therapeutics announced that it would test its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus in preclinical studies.

February

On February 11, the Company announced that it had drawn down a fourth tranche under its convertible note agreement with Negma Group LTD and Park Partners GP.
On February 24, the Company provided an update on the pre-clinical testing of stenoparib’s antiviral activity against new variants of Coronavirus.
March

On March 3, the Company published that it had initiated a Phase 2 trial of IXEMPRA in Europe for the treatment of metastatic breast cancer.
On March 9, the Company announced positive data from a preclinical study of dovitinib in osteosarcoma.
On March 23, the Company announced plans of fully guaranteed rights issue of approximately SEK 100 million.
On March 31, the Company published its annual report for 2020.
On March 31, the Company published a notice to convene the Annual General Meeting to be held on Thursday 15 April 2021 at 15:00 (CEST).

Highlights after the period

April

On April 2, the Company submitted a PreMarket Approval (PMA) application to the U.S. FDA for the DRP companion diagnostic for dovitinib.
On April 15, the Company published the minutes of the Annual General Meeting 2021.
On April 29, the Company announced that a Dovitinib-DRP e-Poster will be presented at the European Association for Cancer Research (EACR) 2021 Virtual Congress to be held from 9-12 June 2021.

May

On May 19, the Company announced that it would conduct a Rights Issue of new shares, and it had published a prospectus regarding the Rights Issue.
On May 21, the Company announced that it had secured an investment from 3i Fund for recapitalization, transition to listing on U.S. Nasdaq, and advancing the company’s pipeline of priority oncology therapeutics.
The report is available on: View Source

Online webcast/conference call

Allarity Therapeutics will host a live webcast on 28 May 2021, at 5:00 p.m. CEST to discuss the company’s first-quarter 2021 results and provide a business and financial update.

Attendees are encouraged to pre-register in order to be able to watch the presentation slides using this link: View Source

On May 28, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations (Press release, Spectrum Pharmaceuticals, MAY 28, 2021, View Source [SID1234583270]). This poster presentation will be available at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting being held June 4-8, 2021. Details of the presentation is as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations
Speaker: Xiuning Le, M.D., Ph.D.
Poster Session: Lung Cancer – Non-small Cell Metastatic
Date and Time: June 4, 2021, available for on demand viewing beginning at 9 a.m. ET
Abstract Number: 9093

The poster presentations will be available for viewing by registered participants during the conference via the ASCO (Free ASCO Whitepaper) website beginning on June 4, 2021.

On May 28, 2021, Viracta Therapeutics, Inc. (the "Company") reported that entered into an Open Market Sale AgreementSM (the "Sale Agreement") with Jefferies LLC (the "Sales Agent"), under which the Company may offer and sell up to $50,000,000 of shares (the "Shares") of its common stock, par value $0.0001 per share ("Common Stock"), from time to time through the Sales Agent, acting as the Company’s sales agent (Filing, 8-K, Sunesis, MAY 28, 2021, View Source [SID1234583269]). The sales and issuances, if any, of the Shares by the Company under the Sale Agreement is subject to the effectiveness of the Company’s registration statement on Form S-3 (the "Registration Statement"), filed with the Securities and Exchange Commission on May 28, 2021. The Company makes no assurances as to if or whether the Registration Statement will become effective or, if it does become effective, as to the continued effectiveness of the Registration Statement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sales, if any, of the Shares pursuant to the Sale Agreement may be made in negotiated transactions or transactions that are deemed to be "at the market offerings" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on The Nasdaq Stock Market, or sales made into any other existing trading market for the Common Stock. The Sales Agent is not required to sell any specific amount of securities, but will act as the Company’s sales agent using commercially reasonable efforts to sell the Shares from time to time (the "Offering"), consistent with its normal trading and sales practices, applicable state and federal laws, rules and regulations and the rules of The Nasdaq Stock Market, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company has agreed to pay the Sales Agent a commission equal to 3.0% of the aggregate gross proceeds from each sale of Shares pursuant to the Sale Agreement and to provide the Sales Agent with customary indemnification and contribution rights, including for liabilities under the Securities Act. In addition, the Company has agreed to reimburse certain expenses incurred by the Sales Agent in connection with the Offering. The Sales Agent’s obligations to sell the Shares under the Sale Agreement are subject to satisfaction of certain conditions, including customary closing conditions.

The Company is not obligated to sell any of the Shares under the Sale Agreement and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by the Company at any time by giving 10 days’ written notice to the Sales Agent for any reason or by the Sales Agent at any time by giving 10 days’ written notice to the Company for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the Shares.

The foregoing description of the Sale Agreement is not complete and is qualified in its entirety by reference to the full text of the Sale Agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On May 28, 2021 Amgen (NASDAQ:AMGN) reported that it will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday, June 3, 2021 (Press release, Amgen, MAY 28, 2021, View Source [SID1234583268]). Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.